clinical trial · NCT06878833
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
SchizophreniaSchizoaffective DisorderLYN-005 (risperidone)Placebo for LYN-005IR RisperidonePlacebo for IR Risperidone
brief summary
Lyndra Therapeutics, Inc., is developing a long-acting oral (LAO) treatment of risperidone (LYN-005) in a capsule dosage form (LYNX® drug delivery platform). The intent of LYN-005 is to reduce the dosing frequency of orally-administered risperidone to once weekly or less and, thereby improve treatment adherence and management of schizophrenia and schizoaffective disorder. This study will evaluate the safety and tolerability of multiple administrations of LYN-005 at 3 dose levels.
started
Apr 18, 2025
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Apr 8, 2025
official title
A Multidose, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol